Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio.

The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge.

It will use the LENSai Full Suite of Integrated Intelligence Technology from Immunoprecise Antibodies’ subsidiary BioStrand with the Multifunctional Polymeric Nanocapsules (MPN Technology) of Libera Bio.

The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.

The nanocapsules are designed specifically around the antibodies’ physicochemical properties, for protecting them from degradation in the bloodstream.

Additionally, MPNs can provide other biologic modalities or combinations of a biologic as well as a small molecule in the same nanocapsule.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

They deliver the compounds through a cell membrane and to intracellular targets.

Under the collaboration, Libera Bio and Talem Therapeutics will together develop new antibodies for use with MPN delivery.

These antibodies will be provided to pharma companies for conducting late-stage development and marketing.

They will investigate two intracellular targets with high unmet patient requirements for providing options to the oncologists who treat them.

Immunoprecise Antibodies CEO and president Dr Jennifer Bath said: “As we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the ‘Holy Grail’ in oncology.

“Libera Bio’s ground-breaking approach of enabling biologics to penetrate the cell membrane and reach previously ‘undruggable’ targets is an exciting development that has the potential to transform the way we treat cancer.”